When an impressive opening act at the professional level and strong performances at the U23 camp string together, a first ...

A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

MacDonald and MacVicar, who were recognized during the recent athletic awards dinner, represented Charlottetown-based Colonel ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the world, with a market cap of more than $650 billion. But there's still ...

May 27 (Reuters) - Eli Lilly (LLY.N), opens new tab will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. Wegovy was first to market but ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Houston-based Empower Pharmacy is one of two compounding pharmacies sued by the pharmaceutical giant Eli Lilly earlier this month for allegedly selling "knockoff" versions of its weight loss and ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...